Identity
- Security key
- 11413
- Ticker
- AGIO
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2013-07-24
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- AGIO
Detail
Enriched 2026-08-14 20:47
- Market cap
- $2,042,401,383.22
- Shares outstanding (class)
- 59,701,882
- Shares outstanding (weighted)
- 59,701,882
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 540
- Location
- CAMBRIDGE, MA
- Homepage
- https://www.agios.com
- Description
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Market cap and share counts drift.